Addus HomeCare Corporation (ADUS)vsNovartis AG ADR (NVS)
ADUS
Addus HomeCare Corporation
$92.10
+2.68%
HEALTHCARE · Cap: $1.83B
NVS
Novartis AG ADR
$148.38
-0.96%
HEALTHCARE · Cap: $273.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 3806% more annual revenue ($56.58B vs $1.45B). NVS leads profitability with a 23.9% profit margin vs 6.9%. ADUS appears more attractively valued with a PEG of 0.96. ADUS earns a higher WallStSmart Score of 60/100 (C+).
ADUS
Buy60
out of 100
Grade: C+
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-7.7%
Fair Value
$104.58
Current Price
$92.10
$12.48 premium
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
6.9% margin — thin
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : ADUS
The strongest argument for ADUS centers on Altman Z-Score, Debt/Equity, PEG Ratio. PEG of 0.96 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : ADUS
The primary concerns for ADUS are Market Cap, Profit Margin.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
ADUS profiles as a value stock while NVS is a declining play — different risk/reward profiles.
ADUS carries more volatility with a beta of 0.92 — expect wider price swings.
ADUS is growing revenue faster at 7.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
ADUS scores higher overall (60/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Addus HomeCare Corporation
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Addus HomeCare Corporation, provides personal care services to the elderly, the chronically ill, the disabled, and people who are at risk of hospitalization or institutionalization in the United States. The company is headquartered in Frisco, Texas.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?